67 related articles for article (PubMed ID: 21332407)
1. Comparative proteomic analysis of advanced serous epithelial ovarian carcinoma: possible predictors of chemoresistant disease.
Kim SW; Kim S; Nam EJ; Jeong YW; Lee SH; Paek JH; Kim JH; Kim JW; Kim YT
OMICS; 2011 May; 15(5):281-92. PubMed ID: 21332407
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
[TBL] [Abstract][Full Text] [Related]
3. Elevated expression of astrocyte elevated gene-1 (AEG-1) is correlated with cisplatin-based chemoresistance and shortened outcome in patients with stages III-IV serous ovarian carcinoma.
Li C; Li Y; Wang X; Wang Z; Cai J; Wang L; Zhao Y; Song H; Meng X; Ning X; Xu C; Lin M; Li L; Geng J
Histopathology; 2012 May; 60(6):953-63. PubMed ID: 22372608
[TBL] [Abstract][Full Text] [Related]
4. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
[TBL] [Abstract][Full Text] [Related]
5. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
6. Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma.
Nymoen DA; Hetland Falkenthal TE; Holth A; Ow GS; Ivshina AV; Tropé CG; Kuznetsov VA; Staff AC; Davidson B
Gynecol Oncol; 2015 Oct; 139(1):30-9. PubMed ID: 26232338
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas.
Têtu B; Popa I; Bairati I; L'Esperance S; Bachvarova M; Plante M; Harel F; Bachvarov D
Mod Pathol; 2008 Aug; 21(8):1002-10. PubMed ID: 18500265
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas.
Yakirevich E; Sabo E; Naroditsky I; Sova Y; Lavie O; Resnick MB
Gynecol Oncol; 2006 Jan; 100(1):152-9. PubMed ID: 16198399
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
11. Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease.
Kim SW; Kim JW; Kim YT; Kim JH; Kim S; Yoon BS; Nam EJ; Kim HY
Genes Chromosomes Cancer; 2007 Jan; 46(1):1-9. PubMed ID: 17044060
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
13. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma.
Li XQ; Zhang SL; Cai Z; Zhou Y; Ye TM; Chiu JF
Cancer Lett; 2009 Mar; 275(1):109-16. PubMed ID: 19056166
[TBL] [Abstract][Full Text] [Related]
14. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
15. Combination of serum hCG beta and p53 tissue expression defines distinct subgroups of serous ovarian carcinoma.
Vartiainen J; Lassus H; Lehtovirta P; Finne P; Alfthan H; Butzow R; Stenman UH
Int J Cancer; 2008 May; 122(9):2125-9. PubMed ID: 18098286
[TBL] [Abstract][Full Text] [Related]
16. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy.
Bachvarov D; L'esperance S; Popa I; Bachvarova M; Plante M; Têtu B
Int J Oncol; 2006 Oct; 29(4):919-33. PubMed ID: 16964388
[TBL] [Abstract][Full Text] [Related]
17. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
19. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival.
Choi CH; Choi JJ; Park YA; Lee YY; Song SY; Sung CO; Song T; Kim MK; Kim TJ; Lee JW; Kim HJ; Bae DS; Kim BG
Br J Cancer; 2012 Jun; 107(1):91-9. PubMed ID: 22644307
[TBL] [Abstract][Full Text] [Related]
20. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
